Yesterday DKTI made an announcement regarding the ongoing talks with Dandrit A/S. Apparantly the status of DKTI a7s as an investment company raises some tax-issues with regard to the proposed merger.

The solution has therefore been that  Dandrit shareholders get new shares in DKTI A/S (a swap if you will). General Assembly to be held in Q3.

Effectively this is the birth of a new danish listed company, researching in cutting-edge technology within the very attractive onchology area. And a company that is working with cancer vaccine

About Stengaard

BioPorto investor from way back when... I've invested in BioPorto ever since they made their debut on the danish stock exchange, it been a looooong journey with many obstacles. But well worth it all if Bioporto maintains their patent after the proceedings in 2014, and enters into agreements with Global Distributors in 2012 and 2013 If not, then it'll take another xx.years 🙂


Leave a Reply

Your email address will not be published. Required fields are marked *

Set your Twitter account name in your settings to use the TwitterBar Section.